|
|
Volume 1, Issue 2, October 1994, in PDF
|
   |
Article 5: Sandoz Developing New Strategy for Siting Phase III Trials
- "Portfolio" approach will rank candidate investigators based on past performance in three areas: speed, quality, and cost.
- Only higher-ranked investigators will win contracts.
- Study shows portfolio approach will result in improved data quality, lower study costs per patient, and quicker completion of Phase III trials.
Article 6: Sponsors Turning More Critical of Investigators' Performance
- Sponsors using more systematic methods to measure investigators' performance.
- Over 35 U.S. pharmaceutical companies now using industry data base to compare center costs.
- Sponsors using Freedom of Information Act to determine if investigators have been cited for deficiencies.
Article 7: Second Thoughts About Thought Leaders
- Poor performance by Thought Leaders has drug companies rethinking how they should use them.
- Analysis of large Phase III trial shows that the Thought Leaders performed poorly in terms of speed and quality, and were more expensive than average.
- Sponsors have an opportunity to improve clinical trials process by making more judicious use of Thought Leaders.
Article 8: Private Doctors Launch Nationwide Consortium
- Affiliated Research Centers (ARC) represents 34 centers and 158 investigators.
- Investigator-owned company eyes capturing 50 percent of market for urological clinical research.
- The company expects to launch nationwide consortiums in 11 other fields.
Price: $59.00
|
|
|
